Navidea Biopharmaceuticals, Inc.
NAVB · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $36 | $36 | $0 | $50 |
| Gross Profit | -$36 | -$36 | $0 | -$49 |
| % Margin | – | – | – | -8,102.6% |
| R&D Expenses | $830 | $1,106 | $1,267 | $1,890 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1,302 | $1,321 | $1,155 | $1,259 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$145 | $0 | $0 |
| Operating Expenses | $2,131 | $2,428 | $2,422 | $3,149 |
| Operating Income | -$2,131 | -$2,428 | -$2,422 | -$3,198 |
| % Margin | – | – | – | -524,298.4% |
| Other Income/Exp. Net | -$124 | $1,035 | $946 | -$284 |
| Pre-Tax Income | -$2,255 | -$1,393 | -$1,476 | -$3,483 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2,255 | $6,032 | -$1,476 | -$3,483 |
| % Margin | – | – | – | -570,922.8% |
| EPS | -0.023 | 0.12 | -0.045 | -0.11 |
| % Growth | -118.9% | 365.5% | 58.9% | – |
| EPS Diluted | -0.023 | 0.12 | -0.045 | -0.11 |
| Weighted Avg Shares Out | 99,364 | 48,243 | 32,654 | 32,376 |
| Weighted Avg Shares Out Dil | 99,364 | 48,243 | 32,654 | 32,377 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $614 | $0 | $0 |
| Interest Expense | $103 | $0 | $263 | $246 |
| Depreciation & Amortization | $27 | $36 | $28 | $26 |
| EBITDA | -$2,104 | -$2,401 | -$1,186 | -$3,200 |
| % Margin | – | – | – | -524,539.7% |